Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Zanubrutinib

Review the clinical trials studying zanubrutinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 29

Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Location: 225 locations
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 18 locations
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Status: Active
Location: 11 locations
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Status: Active
Location: 13 locations
Zanubrutinib, Obinutuzumab, and Venetoclax in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma
Status: Active
Location: 9 locations
Mosunetuzumab Alone or with Zanubrutinib for the Treatment of Newly Diagnosed Follicular Lymphoma
Status: Active
Location: 9 locations
Zanubrutinib in Combination with Sonrotoclax for the Treatment of Underrepresented Minorities with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Location: 9 locations
Zanubrutinib and Tafasitamab for the Treatment of Relapsed or Untreated Mantle Cell Lymphoma
Status: Active
Location: 8 locations
Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement
Status: Active
Location: 8 locations
Zanubrutinib and Venetoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 7 locations
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Status: Active
Location: 6 locations
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 5 locations
Zanubrutinib, Bendamustine, and Rituximab for the Treatment of Previously Untreated Waldenstrom Macroglobulinemia, ZEBRA Trial
Status: Active
Location: 5 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: 5 locations
BRAZAN Induction Therapy Followed by Zanubrutinib and Rituximab Maintenance Therapy with or without Sonrotoclax for the Treatment of Mantle Cell Lymphoma
Status: Active
Location: 4 locations
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Status: Active
Location: 2 locations
Epcoritamab, Zanubrutinib, and Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Status: Active
Location: 2 locations
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Recurrent or Refractory Richter's Syndrome
Status: Active
Location: 2 locations
Rituximab and Zanubrutinib for the Treatment of Patients with Marginal Zone Lymphoma or Follicular Lymphoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Zanubrutinib, Obinutuzumab, and Sonrotoclax for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Mosunetuzumab and Zanubrutinib for the Treatment of Patients with Relapsed or Refractory Marginal Zone Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Zanubrutinib with R-CHOP for the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Tazemetostat in Combination with Zanubrutinib and Rituximab or Obinutuzumab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia or Follicular Lymphoma, TARZAN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah